The U.S. Food and Drug Administration granted priority review for two supplemental applications for Merck's (NYSE: MRK) KEYTRUDA and KEYTRUDA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE